Prothena (PRTA)
NASDAQ:PRTA
Want to see PRTA full AI Analyst Report?
PRTA Stock Chart & Stats
$10.90
<$0.01(0.07%)
At close: 4:00 PM EST
$10.90
<$0.01(0.07%)
Day’s Range― - ―
52-Week Range$4.95 - $11.80
Previous CloseN/A
Volume58.73K
Average Volume (3M)732.47K
Market Cap
$432.44M
Enterprise Value$211.15M
Total Cash (Recent Filing)$329.46M
Total Debt (Recent Filing)$7.65M
Price to Earnings (P/E)―
Beta1.04
Next Earnings
Aug 10, 2026EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.81
Shares Outstanding52,353,237
10 Day Avg. Volume686,318
30 Day Avg. Volume732,465
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)1.83
Price to Sales (P/S)53.08
P/FCF Ratio-3.14
Enterprise Value/Market Cap0.49
Enterprise Value/Revenue3.64
Enterprise Value/Gross Profit7.78
Enterprise Value/Ebitda-2.83
Forecast
1Y Price Target
$21.40Price Target Upside96.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)0.25
Revenue Forecast (FY)$87.90M
Bulls Say, Bears Say
Bulls Say
Balance Sheet Strength (low Leverage)Consistently very low leverage gives Prothena financing optionality and a longer runway versus highly leveraged peers. Over a multi‑month horizon this reduces default risk, supports continued R&D investment, and makes it easier to negotiate partnerships or contingent funding when clinical milestones require cash.
Collaborative, Milestone-driven Revenue ModelA partnership/licensing business model creates multiple non‑commercial revenue pathways (upfronts, R&D reimbursement, milestones, royalties). Structurally this lets Prothena focus on discovery and clinical development without building large commercial infrastructure, while enabling material cash inflows when programs hit milestones.
Governance Continuity And Auditor RatificationReaffirmation of the board and an independent auditor signals stable governance and oversight. For a clinical‑stage biotech, consistent leadership and credible financial controls enhance partner confidence and reduce execution risk across multi‑year trials and licensing negotiations.
Bears Say
Persistent Negative Cash FlowSustained negative operating and free cash flow forces Prothena to rely on external financing or partner payments to fund operations. Over several months this increases dilution or refinancing risk, constrains capital for parallel trials, and makes long‑term program continuity contingent on successful funding events.
Negative Gross Profit And Deep Operating LossesA negative trailing gross profit indicates the core cost structure and R&D spending currently outstrip revenue. Persistent operating losses erode equity and limit the company's ability to self‑finance clinical development, raising structural sustainability concerns absent material milestone receipts or financing.
Highly Volatile, Episodic RevenueRevenue that depends on milestone timing creates lumpy cash inflows, complicating budgeting and multi‑year trial planning. This structural volatility increases funding uncertainty during troughs, elevates the importance of external financing, and can delay programs if expected collaborator payments are not timely.
Prothena News
PRTA FAQ
What was Prothena’s price range in the past 12 months?
Prothena lowest stock price was $4.95 and its highest was $11.80 in the past 12 months.
What is Prothena’s market cap?
Prothena’s market cap is $432.44M.
When is Prothena’s upcoming earnings report date?
Prothena’s upcoming earnings report date is Aug 10, 2026 which is in 58 days.
How were Prothena’s earnings last quarter?
Prothena released its earnings results on May 07, 2026. The company reported $0.6 earnings per share for the quarter, beating the consensus estimate of -$0.348 by $0.948.
Is Prothena overvalued?
According to Wall Street analysts Prothena’s price is currently Undervalued.
Does Prothena pay dividends?
Prothena does not currently pay dividends.
What is Prothena’s EPS estimate?
Prothena’s EPS estimate is -0.39.
How many shares outstanding does Prothena have?
Prothena has 52,353,237 shares outstanding.
What happened to Prothena’s price movement after its last earnings report?
Prothena reported an EPS of $0.6 in its last earnings report, beating expectations of -$0.348. Following the earnings report the stock price went up 1.996%.
Which hedge fund is a major shareholder of Prothena?
Currently, no hedge funds are holding shares in PRTA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Prothena Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$21.40 (96.33% Upside)
$21.40 (96.33% Upside)
Hedge Fund Trend
Decreased
By 14.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $2.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.0%
Last 30 Days ▼ 1.2%
Last 30 Days ▼ 1.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-39.39%
12-Months-Change
Fundamentals
Return on Equity
-49.88%
Trailing 12-Months
Asset Growth
-29.36%
Trailing 12-Months
Company Description
Prothena
Established in 2012 and headquartered in Dublin, Ireland, Prothena Corporation plc functions as a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapeutic solutions for critical, life-threatening conditions, primarily within the United States. The company's pipeline features several key programs: Birtamimab, an investigational humanized antibody, is currently undergoing Phase III clinical trials for the treatment of AL amyloidosis. Prasinezumab, a humanized monoclonal antibody, is progressing through Phase IIb trials for Parkinson's disease. Prothena has also completed Phase I clinical trials for PRX004, indicated for Transthyretin amyloidosis, and is advancing PRX005 through Phase I for Alzheimer's disease. In its earlier-stage development, Prothena is exploring PRX012 for Alzheimer's disease, alongside a dual Aß-Tau vaccine designed for both the treatment and prevention of Alzheimer's disease. Prothena maintains strategic partnerships, including a comprehensive license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. for antibodies targeting alpha-synuclein. The company also collaborates with Bristol-Myers Squibb on antibody development.
PRTA Company Deck
PRTA Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful scientific and business progress — two partner programs advanced to Phase III, strong Phase II biomarker signals (40% reduction in a PD motor endpoint subset; 48% NT‑proBNP reduction for coramitug), introduction of a novel CYTOPE technology with encouraging preclinical TDP‑43 results, and a solid year‑end cash position ($308.4M). Material near‑term upside exists (up to $105M in 2026 milestones and ~ $3B in potential future milestones across partners). Offsetting risks include ARIA‑E safety concerns for PRX012 prompting re‑engineering, some non‑statistically significant secondary endpoints (6‑minute walk test), multi‑year timelines to Phase III primary completions (2029), continued net losses and burn, and reliance on partner decisions for key programs (PRX019). Overall, positives — pipeline advancement, strong partner validation, and a healthy cash balance — outweigh the operational and timing risks.View all PRTA earnings summariesPRTA Stock 12 Month Forecast
Average Price Target
$21.40
▲(96.33% Upside)
Technical Analysis
Lexicon Pharmaceuticals
―
XOMA Royalty Corporation
―
Zevra Therapeutics
―
Corvus Pharmaceuticals
―
Alumis Inc.
―
Ownership Overview
3.30% Insiders
20.06% Mutual Funds
23.70% Other Institutional Investors
43.39% Public Companies and
Individual Investors